Carl M. Gay
A5057753889- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Cancer therapeutics and mechanisms
- Cancer Mechanisms and Therapy
- Cancer Immunotherapy and Biomarkers
- Microtubule and mitosis dynamics
- Phagocytosis and Immune Regulation
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Medical Imaging and Pathology Studies
- Occupational and environmental lung diseases
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Advanced Breast Cancer Therapies
- Calcium signaling and nucleotide metabolism
- Computational Drug Discovery Methods
- Radiomics and Machine Learning in Medical Imaging
- Pharmaceutical studies and practices
- Viral Infections and Outbreaks Research
- Colorectal Cancer Treatments and Studies
- PARP inhibition in cancer therapy
- Cytokine Signaling Pathways and Interactions
The University of Texas MD Anderson Cancer Center
2016-2025
ORCID
2021
Cedars-Sinai Medical Center
2021
NYU Langone Health
2010-2019
John Wiley & Sons (United States)
2019
The University of Texas Health Science Center at Houston
2014
Brigham and Women's Hospital
2014
New York University
2011
Abstract Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining chest cavity. To expand our understanding MPM, we conducted comprehensive integrated genomic study, including most detailed analysis BAP1 alterations to date. We identified histology-independent molecular prognostic subsets, and defined novel subtype with TP53 SETDB1 mutations extensive loss heterozygosity. also report strong expression immune-checkpoint gene VISTA in epithelioid strikingly higher than...
Abstract Although treatment with immune checkpoint inhibitors provides promising benefit for patients cancer, optimal use is encumbered by high resistance rates and requires a thorough understanding of mechanisms. We observed that tumors treated PD-1/PD-L1 blocking antibodies develop through the upregulation CD38, which induced all-trans retinoic acid IFNβ in tumor microenvironment. In vitro vivo studies demonstrate CD38 inhibits CD8+ T-cell function via adenosine receptor signaling or...
Highlights•SCCs show chromosome or methylation alterations affecting multiple related genes•These regulate squamous stemness, differentiation, growth, survival, and inflammation•Copy-quiet SCCs have hypermethylated (FANCF, TET1) mutated (CASP8, MAPK-RAS) genes•Potential targets include ΔNp63, WEE1, IAPs, PI3K-mTOR/MAPK, immune responsesSummaryThis integrated, multiplatform PanCancer Atlas study co-mapped identified distinguishing molecular features of cell carcinomas (SCCs) from five sites...
Small cell lung cancer (SCLC) is one of the most aggressive forms cancer, with a 5-year survival <7%. A major barrier to progress absence predictive biomarkers for chemotherapy and novel targeted agents such as PARP inhibitors. Using high-throughput, integrated proteomic, transcriptomic, genomic analysis SCLC patient-derived xenografts (PDXs) profiled lines, we identified drug sensitivity determined their prevalence in patient tumors. In contrast breast ovarian inhibitor response was not...
Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. We investigated oncogene-specific differences in these markers and clinical outcome. Methods Three cohorts of NSCLC with (n=4189 total) were analyzed. Two advanced treated ICB monotherapy [MD Anderson (MDACC; n=172) Flatiron Health-Foundation...
IntroductionProgrammed death-ligand 1 (PD-L1) expression may vary in different disease sites and at time points of the course. We aimed to investigate PD-L1 heterogeneity its usefulness as a predictive value for immune checkpoint inhibitor (ICI) therapy patients with NSCLC.MethodsPD-L1 was analyzed 1398 NSCLC. The ICIs 398 metastatic NSCLC assessed.ResultsPD-L1 significantly associated biopsy (p = 0.004). Adrenal, liver, lymph node (LN) metastases had highest continuous variable 1% or 50%...
Abstract Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell lung cancer (NSCLC). The impact of adding to neoadjuvant Nivo+CT is unknown. Here we report the results correlates two arms phase 2 platform NEOSTAR trial testing Ipi+Nivo+CT major (MPR) as primary endpoint. MPR were 32.1% (7/22, 80% confidence interval (CI) 18.7–43.1%) arm 50% (11/22, CI 34.6–61.1%) arm; endpoint...
Abstract Small-cell lung cancer (SCLC) is the most aggressive and lethal subtype of cancer, for which, better understandings its biology are urgently needed. Single-cell sequencing technologies provide an opportunity to profile individual cells within tumor microenvironment (TME) investigate their roles in tumorigenic processes. Here, we performed high-precision single-cell transcriptomic analysis ~5000 from primary tumors (PTs) matched normal adjacent tissues (NATs) 11 SCLC patients,...
Only around 20-30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue availability, and tumour heterogeneity, radiographic images might holistically capture the underlying biology. We aimed to investigate application deep learning on chest CT scans derive an imaging signature response immune checkpoint inhibitors evaluate its added value in...
Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct transcriptional subtypes, but implementing subtyping in the clinic has remained challenging, particularly due to limited tissue availability. Given known epigenetic regulation critical SCLC programs, we hypothesized that subtype-specific patterns DNA methylation could be detected tumor or blood from patients. Using genomic-wide reduced-representation bisulfite sequencing (RRBS) two cohorts totaling 179 patients...
Here, we have investigated treatment resistance mechanisms in small cell lung cancer (SCLC) by focusing on comparing the genotype and phenotype tumor samples of treatment-resistant treatment-sensitive SCLC.We conducted whole-exome sequencing paired at diagnosis relapse from 11 patients with limited-stage (LS)-SCLC targeted 1,021 cancer-related genes cell-free DNA baseline relapsed 9 additional LS-SCLC. Furthermore, performed label-free mass spectrometry-based proteomics 28 chemo-resistant 23...
Abstract Purpose: This study investigated the efficacy and safety of oral PARP inhibitor veliparib, plus carboplatin etoposide in patients with treatment-naïve, extensive-stage small cell lung cancer (ED-SCLC). Patients Methods: were randomized 1:1:1 to veliparib [240 mg twice daily (BID) for 14 days] chemotherapy followed by maintenance (400 BID; throughout), placebo (veliparib combination only), or (control). received 4–6 cycles therapy, then until unacceptable toxicity/progression. The...
Abstract The role of combination chemotherapy with immune checkpoint inhibitors (ICI) (ICI-chemo) over ICI monotherapy (ICI-mono) in non-small cell lung cancer (NSCLC) remains underexplored. In this retrospective study 1133 NSCLC patients, treatment ICI-mono vs ICI-chemo associate higher rates early progression, but similar long-term progression-free and overall survival. Sequential concurrent have survival, suggesting no synergism from therapy. Integrative modeling identified PD-L1, disease...